PharmacoEconomics & Outcomes News 402 - 8 Mar 2003

Sales growth over next 3 yearspredicted by Amgen

Over the next 3 years, Amgen is predicting an increasein global sales of approximately 30–32%.

Amgen, the world’s largest biotechnology company,expects the continued growth of several key productswill drive the company’s success. A 20% annual increasein sales is expected for its antianaemic agentsdarbepoetin alfa [‘Aranesp’] and epoetin alfa [‘Epogen’]over the forecast period, while combined sales growthin the low- to mid-20% range is expected for itsgranulocyte colony-stimulating factors filgrastim[‘Neupogen’] and pegfilgrastim [‘Neulasta’]. Salesgrowth of 90% per year is expected for Amgen’s arthritisagent etanercept [‘Enbrel’] over the next 3 years. Thepredictions are in contrast to the industry trend, with anumber of pharmaceutical giants reporting poorforecasts for the months ahead.Amgen forecasts financial boom. Pharma Times : [1 page], 27 Feb2003 800925236

1

PharmacoEconomics & Outcomes News 8 Mar 2003 No. 4021173-5503/10/0402-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved